Related by context. All words. (Click for frequent words.) 70 multicenter randomized controlled 69 ExTRACT TIMI 68 RE LY 68 TAXUS ATLAS 67 SPIRIT IV 67 EVEREST II 67 Multicenter Automatic Defibrillator Implantation 66 SPIRIT III 66 EURIDIS 66 ACRIN 66 multicenter randomized clinical 65 TRITON TIMI 65 BCIRG 65 ENDEAVOR IV 65 CARE HF 65 multicenter phase 65 multicenter prospective 65 NSABP B 65 ENDEAVOR III 65 prospective multicenter 65 placebo controlled Phase 64 ENDEAVOR II 64 placebo controlled clinical 64 RE LY ® 64 PREVENT IV 64 Phase 1a clinical 64 phase IIIb 64 multicenter Phase 64 Phase III VISTA 64 Myocardial Infarction Study 64 SPIRIT FIRST 64 registrational Phase 64 Intervention Effectiveness 64 HORIZONS AMI trial 64 Clinical Antipsychotic Trials 64 Carotid Revascularization Endarterectomy vs. 64 RECORD1 64 ONTARGET 64 CAMMS# 64 STRIDE PD 64 PERSEUS 64 CLARITY TIMI 63 MADIT II 63 ENDEAVOR IV clinical 63 ACCORD Lipid 63 HORIZONS AMI 63 Phase Ib clinical 63 viral kinetic 63 ACUITY trial 63 Phase III AFFIRM 63 Randomized controlled 63 TAXUS VI 63 multicentre randomized 63 randomized controlled clinical 63 randomized Phase III 63 prospective randomized controlled 63 Raloxifene Evaluation MORE 63 Multicenter 62 subanalysis 62 PROactive study 62 Randomized Phase 62 Acute Myocardial Infarction 62 Edge STudy 62 CALGB # [002] 62 LUX Lung 62 landmark ATHENA 62 PFO migraine 62 nonrandomized 62 PARTNER Trial 62 phase IIa clinical 62 AVADO 62 National Emphysema Treatment 62 HCV SPRINT 62 SWOG 62 Phase III randomized controlled 62 dose escalation clinical 62 CHARM Added 62 Intervention Effectiveness CATIE 62 Long Lesion 62 SCD HeFT 62 confirmatory clinical 62 CALGB 62 TAXUS IV 61 satraplatin Phase 61 ROCKET AF 61 COPERNICUS 61 BRIM3 61 Prospective Multicenter 61 randomized controlled multicenter 61 Val HeFT 61 Phase III psoriasis 61 placebo controlled Phase III 61 MIST II 61 PRECiSE 61 ICON7 61 TAXUS V 61 Phase 2b kidney transplant 61 double blinded randomized 61 IMPROVE HF 61 Endovascular Valve Edge 61 randomized blinded 61 BARI 2D 61 phase IIb clinical 61 Initiated Phase 61 CALERIE 61 MADIT 61 HYVET 61 AVERROES 61 randomized controlled Phase 61 randomized multicenter trial 61 Prostate Cancer Prevention 61 Randomised 61 AIM HIGH 61 Phase IIB 61 MEND CABG 61 ToGA 61 BRIM2 61 NO# [002] 61 Pivotal Phase III 60 everolimus eluting stent 60 Phase Ib II 60 PROTECT II 60 phase IIa 60 VADT 60 multicenter clinical 60 Randomized Evaluation 60 ENGAGE AF TIMI 60 GISSI HF 60 APEX PD 60 ARBITER 6 60 Digital Mammographic Imaging 60 PRECISE 60 multicenter Phase II 60 HCV RESPOND 2 60 LUMINATE 60 Asthma Intervention 60 multicenter randomized placebo controlled 60 ABSORB trial 60 multicenter Phase III 60 ECASS 60 PROTECT AF 60 PERSEUS clinical program 60 ASCEND HF 60 everolimus eluting stents 60 RTOG 60 MEND CABG II 60 RE LY trial 60 multicenter randomized 60 dose escalation Phase 60 prospective multicenter randomized 60 STEALTH C 60 CATIE AD 60 GetGoal Phase III 60 Glucosamine Chondroitin Arthritis 60 ADMIRE HF 60 Phase IIIb clinical 60 CLARITY study 60 Angiographic 60 Randomized Controlled 60 CAPRIE 60 CHAMPION PCI 60 multicenter placebo controlled 60 ASSERT 60 dosing cohorts 60 substudy 59 DASISION 59 multicentre prospective 59 APPRAISE 59 randomized multicenter 59 Phase #b/#a clinical 59 recurrent GBM 59 Phase III randomized 59 SABCS 59 randomized Phase 2b 59 phase Ib 59 EXPLORE Xa 59 rALLy clinical trial 59 ENESTnd 59 NCT# ClinicalTrials.gov 59 fosbretabulin 59 ALSYMPCA 59 Prospective Randomized Trial 59 BR.# 59 pharmacodynamic PD 59 IMPACT DCM 59 STICH 59 fidaxomicin Phase 3 59 Phase IIIb 59 ongoing Phase 1b 59 prospective multicentre 59 randomized clinical 59 multicenter trials 59 relapsed MM 59 Unstable Angina 59 SYNTAX 59 PreCISe 59 Multicenter Phase 59 evaluable subjects 59 CUSTOM II 59 Aggressive Reduction 59 QUASAR validation study 59 phase III ACCLAIM 59 NSABP 59 Acute Decompensated Heart Failure 59 ALLHAT 58 prospective nonrandomized 58 ADVANCE PD 58 placebo controlled multicenter 58 TG MV 58 undetectable HBV DNA 58 pharmacokinetic PK 58 multicenter multinational 58 ASTEROID 58 Aggressive Drug Evaluation 58 recurrent malignant glioma 58 blinded randomized placebo controlled 58 GOUT 58 RADIANT 58 fidaxomicin Phase 58 controlled multicenter Phase 58 VESTASYNC 58 prospective randomized placebo 58 epoetin alpha 58 Thrombolysis 58 Screening Trial DMIST 58 NICE SUGAR 58 SYNTAX trial 58 subgroup analyzes 58 RE MODEL 58 CUSTOM III 58 XIENCE V demonstrated 58 randomized Phase IIb 58 Phase 2b monotherapy 58 evaluable 58 ABCSG 58 Randomized Phase II 58 secondary efficacy endpoints 58 Randomized phase 58 neratinib 58 blinded randomized 58 prospectively defined 58 ACCOMPLISH 58 Phase IIb III 58 evaluating Actimmune 58 Phase 2a clinical 58 REALITY Trial 58 Phase #/#a 58 Prostate Lung Colorectal 58 Phase 1b clinical 58 ENDEAVOR clinical 58 Pre RELAX AHF 58 BOLDER II 58 mg/m2 dose 58 ILLUMINATE 58 NATRECOR ® 58 prospective observational cohort 58 CRLX# 58 teriflunomide 58 preclinical efficacy 58 ascending dose 58 EchoCRT 58 BiovaxID Phase 58 ACCLAIM COPD 58 Prostate AdenoCarcinoma Treatment 58 SUCCEED trial 58 randomized multicentre 58 PRoFESS 58 phase IIb 57 Intervention Trial 57 Initiate Phase 57 CTRC AACR San Antonio 57 multicenter randomized Phase 57 prospectively randomized 57 Prospective Randomized 57 mg administered orally 57 dosing cohort 57 Advaxis Phase 57 treatment naive genotype 57 neoadjuvant 57 Meta analyzes 57 Aflibercept 57 visceral metastases 57 Randomized Study 57 PRIMO CABG 57 viral kinetics 57 EmbraceAC 57 SIMPADICO 57 CURRENT OASIS 7 57 blinded randomized controlled 57 Breaking Clinical Trials 57 Refractory Angina 57 evaluating REVLIMID 57 galiximab 57 multicentre randomized controlled 57 prospective randomized multicenter 57 assessing T DM1 57 Phase III ADT 57 Percutaneous Coronary Intervention 57 Pegylated Liposomal Doxorubicin 57 TRA 2P 57 Clinical Outcomes Utilizing Revascularization 57 Randomized Phase III 57 TRANSCEND 57 COR Diabetes 57 Left Ventricular Dysfunction 57 Pivotal Phase 57 Radiation Therapy Oncology 57 ORAL Sync 57 Cholesterol Levels SPARCL 57 Primary endpoints 57 Platelet Inhibition 57 PSMA ADC 57 GENASIS clinical 57 Vascugel ® 57 Acute Ischemic Stroke 57 MGd 57 nab paclitaxel 57 SORT OUT III 57 unblinded 57 CIMZIA TM certolizumab pegol 57 prospective longitudinal 57 RIO Lipids 57 evaluating mipomersen 57 evaluating tivozanib 57 Stenting Trial CREST 57 imetelstat 57 prespecified 57 underwent surgical resection 57 recurrent glioblastoma multiforme 57 crizotinib PF # 57 Randomized Double Blind 57 HDL Selective Delipidation 57 Zemplar Capsules 57 GAMMAGARD 57 Val MARC 57 double blinded placebo 57 riociguat 57 PRIMO CABG2 57 NCIC CTG 57 ACCEDE 57 Phase III placebo controlled 56 pharmacokinetics PK 56 Solid Tumors 56 NEO3 56 Patient Outcomes 56 initiated Phase Ib 56 AVOREN 56 EORTC 56 COSTAR II 56 Echocardiographic 56 TQT 56 axitinib 56 PROMUS Element Stent 56 PCPT 56 CYPHER ® Sirolimus eluting 56 Randomized Clinical Trial 56 Pooled Analysis 56 LibiGel Phase III 56 phase 2a 56 NEVO ™ 56 dose escalation phase 56 Digestive Diseases Week 56 DAPT Study 56 Phase 1b 56 angiographic outcomes 56 Amrubicin 56 ANCHOR trial 56 pharmacokinetic pharmacodynamic 56 pharmacokinetic PK study 56 PLCO 56 retrospective observational study 56 Phase 2a trial 56 Spine Patient Outcomes 56 Renal Cell Carcinoma RCC 56 placebo controlled randomized 56 NovoTTF 56 Sorafenib HCC Assessment 56 PreSAP 56 Phase III ThermoDox 56 MERLIN TIMI 56 CaPSURE 56 Phase III HEAT 56 MADIT CRT trial 56 evaluating Vectibix 56 BETAS 56 APEX AMI trial 56 ZACTIMA 56 Carotid Endarterectomy 56 Phase Ib study 56 retrospective cohort 56 sunitinib Sutent 56 Bezielle 56 randomized discontinuation trial 56 placebo controlled studies 56 Controlled Trial 56 Randomized placebo controlled 56 ELACYT 56 DEFER 56 Heart Failure Trial 56 OLYMPIA registry 56 trial evaluating PRX# 56 histologically confirmed 56 sorafenib Nexavar 56 PEG IFN 56 Pivotal Trial 56 Pharmacokinetic 56 MDV# 56 Gynecologic Oncology Group 56 ONTARGET R 56 prospective observational studies 56 CHAMPION PLATFORM 56 Doxil ® 56 AACR San Antonio 56 Coronary Artery Bypass Graft 56 Ovarian PLCO Cancer 56 ELCAP 56 cilengitide 55 BrachySil TM 55 Phase Ib 55 Transcatheter Cardiovascular Therapeutics TCT 55 stage IIIb IV 55 AIR2 Trial 55 prospective observational 55 Phase IIa clinical 55 randomized controlled trials RCTs 55 thorough QT 55 multicentre 55 prospective multicenter study 55 Myocardial Infarction 55 Cloretazine R 55 HPTN 55 MADIT CRT 55 paclitaxel eluting stents 55 Patency 55 TEMSO 55 Group RTOG 55 lorcaserin Phase 55 Multicenter Randomized 55 patients evaluable 55 mg/m2 cohort 55 CYPHER R Sirolimus eluting 55 carotid artery stenting CAS 55 Double Blind Placebo 55 Folfox 55 IMPACT IMmunotherapy 55 trastuzumab emtansine T DM1 55 Ophena TM 55 noninferiority 55 phase IIb study 55 CONSERV 55 ACTIVE W 55 NCCTG 55 placebo controlled dose escalation 55 KRN# 55 zotarolimus eluting stent 55 CLIRS 55 retrospectively analyzed 55 sirolimus eluting stents 55 Vertos II 55 Cloretazine ® 55 ISEL 55 HF ACTION 55 intratumoural 55 randomized multicenter Phase III 55 abstracts summarizing 55 dose cohort 55 AEGR 55 Advanced Neuroendocrine Tumors 55 PCI ExTRACT TIMI 55 XIENCE V PROMUS Stent 55 ALN VSP Phase 55 PRE SURGE 55 metastatic HRPC 55 analgesic efficacy 55 MelaFind pivotal 55 TASKi2 55 TAXUS Liberte Long 55 Combination REOLYSIN R 55 MarginProbe 55 enzastaurin 55 Randomized 55 underwent CABG 55 Phase IIA 55 Xelox 55 blind randomized controlled 55 prospective randomized 55 Transcatheter Cardiovascular Therapeutics 55 TRANSFORMS 55 huC# DM4 55 Multiple Ascending Dose 55 Sequenced Treatment Alternatives 55 mg kg BID 55 OPT CHF 55 ATTRACT 55 ATACAND 55 CYPHER ® Stent 55 tanespimycin 55 underwent resection 55 randomized clinical trials 55 Tarceva TM 55 Adenoma Prevention 55 PROSTVAC TM 55 rALLy trial 55 clinical endpoints 55 arzoxifene 55 afatinib 55 papillary renal cell carcinoma 55 Phase III Psoriasis 55 multicenter randomized double 55 neurologic progression 55 CA9 SCAN 55 Randomized Double Blind Placebo 55 mg BID dose 55 NCCTG N# 55 RECIST Response Evaluation Criteria 55 relapsing multiple sclerosis 55 EDEMA3 55 unfractionated heparin UFH 55 II Clinical Trial 55 prospectively enrolled 55 controlled multicenter 55 TMC# C# 55 pain palliation 55 melphalan prednisone 55 Kaplan Meier analysis 55 Placebo Controlled Trial 55 VICTOR E1 55 CORD II 55 alvespimycin 55 endoscopic remission 55 depsipeptide 55 Xanafide 55 MVax R 55 unblind 55 EINSTEIN DVT 55 COU AA 55 ATTAIN 55 Risk Stratification 55 Dr. Kandzari 55 ARDIS 55 demonstrated clinically meaningful 55 SPARCL 55 DMIST 55 Diabetic Macular Edema 55 POISE 54 pivotal bioequivalence 54 tolvaptan 54 Placebo controlled 54 rFVIIa 54 Phase Ia 54 randomized controlled 54 CLORETAZINE TM VNP#M 54 deforolimus 54 SYMMETRY trial 54 Early Relapsing Multiple 54 IL# PE#QQR 54 interferon gamma 1b 54 multicenter 54 Decompensated Heart Failure 54 Rosuvastatin 54 velafermin 54 Raloxifene STAR 54 dose cohorts 54 preclinical pharmacokinetic 54 Carotid Stenting 54 Screening Trial 54 Tumor Response 54 NEVO 54 Gastrointestinal Cancers Symposium 54 Phase 2b Clinical Trial 54 Bayer HealthCare Onyx Pharmaceuticals 54 ATAC Arimidex Tamoxifen Alone 54 demonstrated antitumor activity 54 Efficacy 54 Trofex 54 ASCO Annual Meeting 54 Phase 1b clinical trials 54 Randomized Double blind 54 Evaluation WISE 54 Events MACE 54 BiTE antibody MT# 54 imetelstat GRN#L 54 CYPHER Stent 54 pertuzumab 54 confirmatory Phase 54 pharmacodynamic effects 54 antibody MAb 54 HIV HCV coinfected 54 huN# DM1 54 dose escalation trial 54 multicentre randomized double 54 CRp 54 Therapeutics TCT scientific 54 SVR# 54 Polyp Prevention Trial 54 Relapsing Multiple Sclerosis 54 Blind Placebo Controlled Trial 54 Successfully Completes Phase 54 dose atorvastatin 54 VITAL Trial 54 Omacetaxine 54 XL# SAR# 54 lorvotuzumab mertansine 54 phase III SIMPADICO 54 resectable pancreatic cancer 54 Subgroup analysis 54 Newly Diagnosed Multiple Myeloma 54 elacytarabine 54 #th Annual Interscience 54 trastuzumab DM1 T DM1 54 Study Evaluating 54 pegylated interferon alfa 2b 54 Thorough QT 54 Romidepsin 54 PEGylated interferon beta 1a 54 ON #.Na 54 KRAS mutations occur 54 ORACLE MS 54 ISAR REACT 54 ER CHOP 54 Liraglutide Effect 54 APF# Phase 54 glufosfamide 54 REVIVE Diabetes 54 Multiethnic Study 54 composite endpoint 54 Phase III multicenter 54 MERIT ES 54 cediranib 54 label multicenter 54 prostate cancer PCa 54 elotuzumab 54 CINQUIL 54 CONQUER OB 54 trastuzumab DM1 54 comparing XIENCE V 54 CLL SLL 54 Dual Antiplatelet Therapy 54 ancrod 54 NEUVENGE 54 F FDG PET 54 Phase III ALLEGRO 54 underwent liver transplantation 54 CCyR 54 delafloxacin 54 Metastatic Melanoma 54 NSABP C 54 pretransplant 54 phase IIb III 54 Stent Restenosis 54 ILLUSTRATE 54 invasive lobular carcinoma 54 relapsing remitting MS RRMS 54 HeFT 54 MAGE A3 ASCI 54 locoregional recurrence 54 cluster randomized controlled 54 Androxal TM 54 Sipuleucel T 54 Free Survival PFS 54 WHIMS 54 TAXUS Liberte Stent 54 farletuzumab 54 Nesiritide 54 Secondary efficacy endpoints 54 dacarbazine chemotherapy 54 relapsed refractory multiple myeloma 54 TASKi3 54 Histopathological 54 tarenflurbil 54 GVAX 54 PROactive Study 54 Phase 2b study 54 heavily pretreated 54 ADHF 54 Maximum Tolerated Dose MTD 54 Neoadjuvant 54 genitourinary cancers 54 Severe Sepsis 54 RESTORE CLI 54 ENVISION 54 neoadjuvant treatment 54 UPLYSO 54 Panzem R NCD 54 oral rivaroxaban 53 NLX P# 53 EGS# 53 EDEMA4 53 Medidur TM FA 53 Phase 2b clinical 53 Eluting 53 nondiabetic patients 53 Phase Ib IIa 53 Daclizumab 53 observational cohort study 53 rALLy 53 efficacy endpoint 53 pharmacodynamic 53 Judith Hochman 53 number NCT# ClinicalTrials.gov 53 meta regression 53 ASH Annual Meeting 53 placebo controlled 53 Cloretazine R VNP#M 53 gemcitabine Gemzar ® 53 FDG-PET/CT 53 Long Term Efficacy 53 MIVI TRUST 53 Teriflunomide 53 concurrent chemoradiation 53 HOPE TOO 53 tolerability pharmacokinetics 53 certolizumab 53 LHRH receptor positive 53 Sibutramine Cardiovascular Outcomes 53 Phase Ib IIa clinical 53 #nd EORTC NCI 53 paclitaxel eluting stent 53 dose escalation 53 Preclinical Study 53 modified REGENESIS Phase IIb 53 randomized 53 Coronary CTA 53 carotid artery stenting 53 5 Fluorouracil 53 RE SURGE 53 mcg albinterferon alfa 2b 53 ritonavir boosted danoprevir 53 clinical trial 53 treatment naïve genotype 53 patients undergoing CABG 53 USpella 53 Prolongs Survival 53 tolevamer 53 WHEL 53 REMINYL ® 53 Alzheimer Disease Cooperative 53 sirolimus eluting 53 Urocortin 2 53 doxorubicin docetaxel 53 Remission Maintenance 53 NABTT 53 ADHERE 53 telaprevir dosing 53 active comparator 53 AS# amonafide L malate 53 clevidipine 53 Complete Remission 53 NATRECOR R 53 fluvastatin 53 INCB# [001] 53 Phase III pivotal 53 RRMS patients 53 pharmacokinetic pharmacodynamic PK PD 53 conducted retrospective cohort 53 aflibercept 53 Phase IIb Clinical Trial 53 colorectal liver metastases 53 ARB telmisartan 53 blind multicenter 53 ZYBRESTAT fosbretabulin 53 ASCO GI 53 AACR IASLC Joint 53 CoFactor 53 FOLFOX4 53 PDX pralatrexate 53 decitabine 53 Trandolapril 53 Phase #b/#a 53 IMPACT DCM clinical 53 INCB# [003] 53 label multicenter Phase 53 J Clin Oncol 53 Kahalalide F 53 anti arrhythmic drug 53 Targeted Therapy 53 PRESEPT 53 #mg/m# [002] 53 REACH Registry 53 Multivessel Evaluation 53 Genitourinary Cancers Symposium 53 oral ridaforolimus 53 Dose Ranging Study 53 NP2 Enkephalin 53 ASCO GU 53 acute STEMI 53 Deforolimus 53 Rheumatology ACR Annual 53 #:# randomization 53 AREDS 53 forodesine 53 Renal Artery 53 medically inoperable 53 unblinding 53 FDG PET imaging 53 AIR CF1 53 ACOSOG Z# 53 skin sterol 53 secondary efficacy endpoint 53 Relapsed Multiple Myeloma 53 KRAS status 53 Metastatic Renal Cell Carcinoma 53 Completes Patient Enrollment 53 pomalidomide 53 #F FDG PET 53 ASCO Breast Cancer 53 NYHA functional class 53 Phase 2b RESTORE CLI 53 liver histology 53 Ovarian Cancer Screening 53 definite stent thrombosis 53 ABSORB clinical 53 confirmed CCyR 53 MACCE 53 Oral Fingolimod 53 adjuvant cisplatin 53 FOLPI 53 masked placebo controlled 53 Hedgehog Pathway Inhibitor 53 MoxDuo TM IR 53 rt PA 53 ACTEMRA TM 53 prognostic variables 53 Diabetic Neuropathy 53 phase Ib clinical 53 Complications Trial 53 HIVNET 53 adenoma recurrence 53 underwent percutaneous coronary 53 Ozarelix 53 Phase Ib Clinical Trial 53 nonmetastatic 53 VICTOR E3 53 Endocrine Society Annual Meeting 53 REYATAZ r arm 53 Infarct 53 Lipid Lowering Treatment 53 Pemetrexed 53 IIa clinical 53 Ischemic 53 Fast Tracked Phase 53 PANVAC VF 53 HBeAg negative patients 53 Arch Surg 53 PERISCOPE 53 TAXUS 53 Quinamed 53 XL# XL# XL# 53 Temsirolimus 53 OvPlex ™ 53 randomized #:#:# 53 RIO Diabetes 53 RCTs 53 PROSTVAC VF 53 carotid endarterectomy CEA 53 Arimidex Tamoxifen Alone 53 AACR NCI EORTC 52 PRECISE trial 52 First Patient Enrolled 52 ONCONASE R 52 Cloretazine 52 pT2 52 urinary N telopeptide 52 sipuleucel T 52 midstage clinical 52 FOLFOX6 chemotherapy regimen 52 paclitaxel cisplatin 52 DermaVir Patch 52 briakinumab 52 VELCADE melphalan 52 placebo controlled trials 52 Pivotal Phase II 52 randomized controlled clinical trials 52 Pharmacodynamic 52 azilsartan medoxomil 52 Pharmacokinetic PK 52 bepotastine besilate nasal spray 52 MTWA testing 52 Heterozygous Familial Hypercholesterolemia 52 IMA# 52 Drug Eluting 52 bazedoxifene conjugated estrogens 52 Stage IIB 52 Zenvia Phase III 52 DCCR 52 Dialysis Outcomes 52 Group B CALGB 52 Valsartan 52 carotid IMT 52 refractory metastatic 52 Tanespimycin 52 REVIVE TA 52 prucalopride 52 varespladib 52 Enzastaurin 52 CIMZIA ™ 52 hormone refractory metastatic prostate 52 Matrix Phase 2b 52 PROLARIS 52 symptomatic VTE 52 ug dose 52 Neuradiab 52 Demonstrates Significant 52 Clinical Outcomes 52 evaluable patients 52 morphometric vertebral fractures 52 Acute Coronary Syndromes ACS 52 pCR 52 dose regimens 52 mm Stent 52 ORENCIA ® 52 Dacogen injection 52 Pimavanserin 52 ECOG 52 HGS ETR2 52 EMPOWER ™ 52 Multi MERCI 52 platinum refractory 52 multicentre phase 52 Edwards SAPIEN valve 52 RCW breast cancer 52 Phase IIIb study 52 graft dysfunction 52 GISSI 52 ischemic cardiomyopathy 52 QTinno 52 selenium supplementation 52 FACIT 52 Intervention Trial GAIT 52 CANCIDAS 52 clinicopathologic 52 CTAP# Capsules 52 TAXUS ARRIVE 52 Phase #b/#a trial 52 OncoVEX GM CSF 52 JAK Inhibitor 52 Tyrima 52 gemcitabine carboplatin 52 Pivotal Trials 52 liver transplant recipients 52 Randomized Controlled Trials 52 Multimeric 52 Second Pivotal Phase 52 beta blocker therapy 52 p# biomarker 52 LAB CGRP 52 Patients Treated With 52 ASCO abstract 52 Systemic Sclerosis 52 DLTs 52 elagolix 52 Antihypertensive 52 longitudinal cohort study 52 TTF Therapy 52 MELD scores 52 LCP Tacro 52 Stenting Trial 52 relapsed MCL 52 Pivotal Study 52 Breaking Clinical Trial 52 Major Adverse Cardiac 52 mITT population 52 Cardiotoxicity 52 INSPIRE Trial Phase III 52 randomized discontinuation 52 postoperative chemotherapy 52 remission CR 52 Phase III Trial 52 Afatinib 52 randomized crossover 52 adjuvant tamoxifen 52 EOquin TM 52 antiretroviral naïve 52 Antiviral Activity 52 fallopian tube cancers 52 budesonide MMX 52 tolerated dose MTD 52 MIVI III 52 DSMB recommended 52 AACR #st Annual Meeting 52 sunitinib malate 52 intradermal injections 52 nucleoside naive patients 52 RESOLUTE 52 R roscovitine 52 urodynamic 52 OHR/AVR# 52 Randomized Controlled Trial 52 CLIRS trial 52 OvaRex R 52 ORBIT II 52 Poster Discussion 52 Tovaxin Phase IIb 52 ISTODAX ® 52 Hormone Refractory Prostate Cancer 52 operable breast cancer 52 Ischemic Stroke 52 PXD# 52 ARCOXIA